儿童患者聚乙二醇干扰素-α-2a治疗后HBV准种特征与乙型肝炎

StephenW

Antivir Ther. 2018 Aug 10. doi: 10.3851/IMP3262. [Epub ahead of print]
Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-alpha-2a treatment in child patients.
Yang J1, Yang G1, He H1, Ning L1, Liu Z1, Fu Q1, Chen H1, Deng H1, Wang Z1, Luo K1.
Author information

1
    Department of Infectious Diseases and Hepatology Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Abstract
BACKGROUND:

The correlation between hepatitis B surface antigen (HBsAg) seroconversion and the characteristics of hepatitis B virus (HBV) quasispecies (QS) before and during pegylated interferon alpha-2a (Peg-IFN-α-2a) treatment in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) children has not yet been reported.
METHODS:

Thirty-five patients, including 18 HBsAg seroconverters (SS) and 17 non-seroconverters (SN), were enrolled. Serum samples were collected before treatment and at weeks 12 and 24 of treatment. Sequences within the basal core promoter/pre-core (BCP/PC) and S/reverse transcriptase (S/RT) region were analyzed by next-generation sequencing.
RESULTS:

There was no significant difference in the baseline diversity of HBV QS (Shannon entropy, Sn; Hamming distance, HD) in either region between the two groups. The baseline mutations A1762T/G1764A, C1913A, and T2003A/G or C2004T were correlated with nonresponse to therapy (p=0.025, p=0.036, p=0.032, respectively). After 24 weeks of therapy, HBV diversity within the BCP/PC region in the SS group notably declined (Sn: p=0.002, HD: p=0.011), while that of the SN group was nearly unchanged. As for the S/RT region, 24 weeks of treatment made no significant difference on QS diversity in either group.
CONCLUSIONS:

Our data demonstrated that the baseline viral mutations and dynamic changes in HBV QS diversity within the BCP/PC region were closely related with HBsAg seroconversion in HBeAg-positive CHB children treated with Peg-IFN-α-2a.

PMID:
    30095435
DOI:
    10.3851/IMP3262

StephenW

Antivir Ther。 2018年8月10日doi：10.3851 / IMP3262。 [提前打印]
儿童患者聚乙二醇干扰素-α-2a治疗后HBV准种特征与乙型肝炎表面抗原血清学转换的关系。
Yang J1，Yang G1，He H1，Ning L1，Liu Z1，Fu Q1，Chen H1，Deng H1，Wang Z1，Luo K1。
作者信息

1
    南方医科大学南方医院传染病与肝病中心，广州

抽象
背景：

乙型肝炎表面抗原（HBsAg）血清转换与乙型肝炎病毒（HBV）准种（QS）在乙型肝炎e抗原（HBeAg）中聚乙二醇化干扰素α-2a（Peg-IFN-α-2a）治疗前后的关系）尚未报道阳性慢性乙型肝炎（CHB）儿童。
方法：

招募了35名患者，包括18名HBsAg血清转换器（SS）和17名非血清转换器（SN）。在治疗前和治疗的第12周和第24周收集血清样品。通过下一代测序分析基础核心启动子/前核心（BCP / PC）和S /逆转录酶（S / RT）区域内的序列。
结果：

在两组之间的任一区域中HBV QS（Shannon熵，Sn; Hamming距离，HD）的基线多样性没有显着差异。基线突变A1762T / G1764A，C1913A和T2003A / G或C2004T与治疗无应答相关（分别为p = 0.025，p = 0.036，p = 0.032）。治疗24周后，SS组BCP / PC区内的HBV多样性显着下降（Sn：p = 0.002，HD：p = 0.011），而SN组的HBV多样性几乎没有变化。对于S / RT区域，24周的治疗对两组的QS多样性没有显着差异。
结论：

我们的数据表明，BCP / PC区域内基线病毒突变和HBV QS多样性的动态变化与用Peg-IFN-α-2a治疗的HBeAg阳性CHB儿童的HBsAg血清转换密切相关。

结论：
    30095435
DOI：
    10.3851 / IMP3262

齐欢畅

帮顶